Our understanding of how FOXM1 inhibitors suppress breast cancer and how breast cancer cells can undermine their effectiveness and acquire resistance should be helpful in directing further studies to move these agents towards translation into the clinic to benefit patients with breast cancer and possibly other cancers driven by FOXM1. The gene discussed is FOXM1; the disease is breast cancer.